Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients

This publication has 20 references indexed in Scilit:

• Chronic Kidney Disease After Nonrenal Solid Organ Transplantation
  Transplantation, 2012
• A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
  Clinical Chemistry, 2011
• The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients
  Cancer Chemotherapy and Pharmacology, 2011
• Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in Korea
  Transplantation, 2009
• Microproteinuria for detecting calcineurin inhibitor-related nephrotoxicity after liver transplantation
  World Journal of Gastroenterology, 2009
• CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study
  American Journal of Transplantation, 2006
• Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose Requirements
  Transplantation, 2006
• Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors
  Pharmacogenetics, 2003
• Urinary protein and enzyme excretion as markers of tubular damage
  Current Opinion in Nephrology and Hypertension, 2003
• FK506 Nephrotoxicity
  Renal Failure, 1999